Approval · Notice of Compliance 27595 · 2022
PLAVIX: Notice of Compliance 27595
Issued February 15, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27595
- Date
- February 15, 2022
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph Conversion of the Product Monograph to 2020 format Removal of the 300 mg strength from the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB